Synthesis and Characterization of a Highly Selective AKR1C3 Inhibitor

Technology #d-1318

Questions about this technology? Ask a Technology Manager

Download Printable PDF

Categories
Researchers
Paul Trippier
Assistant Professor, Department of Pharmaceutical Science, Texas Tech University Health Science Center, Amarillo, Texas
External Link (www.ttuhsc.edu)
Managed By
Cameron Smith
Licensing Associate 806-834-6822
Patent Protection

Provisional Patent Application Filed

The enzyme, aldo-keto reductase family 1-member C (AKR1C3), is a well-known contributor to prostate cancer, acute myeloid leukemia, and chemotherapeutic resistance.  However, current inhibition research has only identified compounds with an insufficient degree of selectivity for AKR1C3 over its other isoforms. 

This invention has established a method of synthesizing an AKR1C3 inhibitor with 1800 fold selectivity over related isoforms and permits more effective cancer treatment.  The research has identified known AKR1C3 inhibitors and altered them to increase selectivity.  Unlike previous AKR1C3 research, the high selectivity of this invention affords a significant likelihood of approval for clinical testing. 

Reference Number: D-1318 

Market Applications:

  • Oncology
  • Pharmaceuticals
  • Cancer treatment research
  • Organic synthesis research 

Features, Benefits & Advantages:

  • Inhibiting AKR1C3 prevents the development of chemotherapeutic resistant cancers
  • Selectivity for AKR1C3 only maintains other healthy and normal hormonal levels
  • Increased survival rates for prostate and breast cancer and AML patients
  • Decreased lengths of hospital stays
  • Reduced treatment costs 

Intellectual Property: A U.S. Provisional Patent application, Serial 62/458,267 was filed on 2/13/17. 

Development Stage: This invention has been reduced to practice and is currently at the proof of concept stage in development. 

Researchers:

  • Paul Trippier, Ph. D., Assistant Professor, Department of Pharmaceutical Science, Texas Tech University Health Science Center, Amarillo, Texas 

Keywords: AKR1C3 inhibitor, Leukemia, Breast Cancer, Prostate Cancer, AKR1C3 Selectivity